The Motley Fool··Reuben Gregg BrewerEli Lilly's GLP-1 Dominance Masks Valuation Risks for Long-Term Investors
Eli Lilly's GLP-1 success masks valuation risks; P/E of 44 leaves little room for competitive pressure and patent cliff execution.
PFELLYNVOGLP-1 drugsgeneric competition